Literature DB >> 30222374

Risk-Based Monitoring: A Closer Statistical Look at Source Document Verification, Queries, Study Size Effects, and Data Quality.

Vadim Tantsyura1, Imogene McCanless Dunn2, Kaye Fendt3, Yong Joong Kim1, Joel Waters4, Jules Mitchel1.   

Abstract

BACKGROUND: Data quality within the clinical research enterprise can be defined as the absence of errors that matter and whether the data are fit for purpose. This concept, proposed by the Clinical Trials Transformation Initiative, resulted from a culmination of collaboration with industry, academia, patient advocates, and regulators, and it emphasizes the presence of a hierarchy of error types, resulting in a more efficient and modern data-cleaning paradigm. While source document verification (SDV) is commonly used as a quality control method in clinical research, it is disproportionately expensive and often leads to questionable benefits. Although the current literature suggests that there is a need to reduce the burden of SDV, there is no consensus on how to replace this "tried and true" practice.
METHODS: This article proposes a practical risk-based monitoring approach based on published statistical evidence addressing the impact of database changes subsequent to SDV.
RESULTS: The analysis clearly demonstrates minimal effects of errors and error corrections on study results and study conclusions, with diminishing effect as the study size increases, and it suggests that, on average, <8% SDV is adequate to ensure data quality, with perhaps higher SDV rates for smaller studies and virtually 0% SDV for large studies.
CONCLUSIONS: It is recommended that SDV, rather than just focusing on key primary efficacy and safety outcomes, focus on data clarification queries as highly discrepant (and the riskiest) data.

Entities:  

Keywords:  clinical trial operations; data quality; risk-based monitoring; site monitoring; source document verification

Year:  2015        PMID: 30222374     DOI: 10.1177/2168479015586001

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  6 in total

1.  Impact of a targeted monitoring on data-quality and data-management workload of randomized controlled trials: A prospective comparative study.

Authors:  Claire Fougerou-Leurent; Bruno Laviolle; Christelle Tual; Valérie Visseiche; Aurélie Veislinger; Hélène Danjou; Amélie Martin; Valérie Turmel; Alain Renault; Eric Bellissant
Journal:  Br J Clin Pharmacol       Date:  2019-12-14       Impact factor: 4.335

Review 2.  Monitoring strategies for clinical intervention studies.

Authors:  Katharina Klatte; Christiane Pauli-Magnus; Sharon B Love; Matthew R Sydes; Pascal Benkert; Nicole Bruni; Hannah Ewald; Patricia Arnaiz Jimenez; Marie Mi Bonde; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2021-12-08

3.  Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study.

Authors:  Sally P Stenning; William J Cragg; Nicola Joffe; Carlos Diaz-Montana; Rahela Choudhury; Matthew R Sydes; Sarah Meredith
Journal:  Clin Trials       Date:  2018-08-22       Impact factor: 2.486

4.  Monitoring performance of sites within multicentre randomised trials: a systematic review of performance metrics.

Authors:  Kate F Walker; Julie Turzanski; Diane Whitham; Alan Montgomery; Lelia Duley
Journal:  Trials       Date:  2018-10-16       Impact factor: 2.279

5.  Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.

Authors:  Andrew Embleton-Thirsk; Elizabeth Deane; Stephen Townsend; Laura Farrelly; Babasola Popoola; Judith Parker; Gordon Rustin; Matthew Sydes; Mahesh Parmar; Jonathan Ledermann; Richard Kaplan
Journal:  Clin Trials       Date:  2019-07-26       Impact factor: 2.486

6.  Research monitoring practices in critical care research: a survey of current state and attitudes.

Authors:  Renate Le Marsney; Tara Williams; Kerry Johnson; Shane George; Kristen S Gibbons
Journal:  BMC Med Res Methodol       Date:  2022-03-21       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.